Can tight blood sugar control fix 'Good' cholesterol in type 1 diabetes?
NCT ID NCT07564752
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether improving blood sugar control in people with type 1 diabetes can restore the normal function of HDL, or 'good' cholesterol. Researchers will compare 80 patients with poorly controlled diabetes who receive standard intensive therapy to 63 healthy people without diabetes. The goal is to see if better glucose management makes HDL work better to protect the heart.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal whether improving blood sugar control restores HDL's protective heart benefits in type 1 diabetes.
- What could go wrong
- This is an observational study, not a treatment trial. It may not prove that better control directly improves heart health, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 143 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with type 1 diabetes whose condition is poorly controlled
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Control group non-diabetic and non-dyslipidemic : * A person who has giver written consent * Fasting blood glucose \< 1,10 g/L * Triglycerides \< 1,50 g/L (\< 1,70 mmol/L). * HDL cholesterol \> 1,03 mmol/L (men) or \> 1,30 mmol/L (women). * LDL cholesterol \< 1,60 g/L. Type 1 diabetes group : * A person who has giver written consent * Treated type 1 diabetes (regardless of the route of insulin administration). * HbA1c \> 8.0% (\> 64 mmol/mol). Exclusion Criteria: All participants : * A person who is not enrolled in or eligible for a social security program * A person subject to a legal protective measure (guardianship, tutorship) * A person subject to a judicial protective measure * Pregnant women, women in labor, or breastfeeding women * Adults who are legally incompetent or unable to give informed consent * Minors * Systemic inflammatory disease * Medications that affect lipoprotein metabolism: immunosuppressive therapy, long-term corticosteroid therapy. Control group non-diabetic and non-dyslipidemic : * Diabetes or use of an antidiabetic medication. * Dyslipidemia or use of lipid-lowering medication. * Cardiovascular disease (history of stroke, myocardial infarction, coronary artery disease). * Kidney disease (glomerular filtration rate CKD-EPI \< 75 mL/min/1.73 m²) * Presence of metabolic syndrome defined by the presence of at least three of the following criteria (NCEP-ATP III criteria): * waist circumference \> 102 cm in men, \> 88 cm in women; * fasting triglycerides \> 1.70 mmol/L ( \> 1.50 g/L); * HDL cholesterol \> 1.03 mmol/L in men and 1.29 mmol/L in women; * systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg; * fasting blood glucose ≥ 6.10 mmol/L (≥ 1.10 g/L). Type 1 diabetes group: * Diagnosis of type 1 diabetes within 12 months prior to enrollment. * Glomerular filtration rate (CKD-EPI) \< 60 mL/min/1.73 m². * Albuminuria ≥ 30 mg/g creatinine. * Initiation of lipid-lowering therapy within the month prior to the study. Exclusion criteria: Type 1 diabetes group: \- Initiation of lipid-lowering therapy during the 3 months of the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chu Dijon Bourgogne
RECRUITINGDijon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Can a math model tune insulin pumps better than standard care?
- Can a group program stop eating disorders in type 1 diabetes?
- Can a Two-Punch immune therapy save insulin cells in newly diagnosed diabetes?
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Can an automated pancreas system make type 1 diabetes safer in the real world?